Agonist Treatment for Opioid Dependence Syndrome: The Impact of Current Understanding upon Recommendations for Policy Initiatives.

OAT harm reduction legislation opioid agonist treatment opioid dependence syndrome policy

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
27 09 2021
Historique:
received: 27 07 2021
revised: 07 09 2021
accepted: 19 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 26 10 2021
Statut: epublish

Résumé

The provision of opioid agonist treatments (OATs), as a standard approach towards opioid dependence syndrome, differs widely between countries. In response to access disparities, in 2014, the Council of Europe's Pompidou Group first brought together an expert group on framework conditions for the treatment of opioid dependence. The group used a Delphi approach to structure their discussions and develop guiding principles for the modernisation of OAT regulations and legislation. The expert group identified some 60 guiding principles, which were then the subject of wide public consultation. Endorsed by Pompidou Group member states, the final report identified four key recommendations: (1) Prescription and delivery without prior authorisation schemes; (2) Effective removal of financial barriers to access to care; (3) Coordination and follow-up by a national consultative body; and (4) Neutral, precise and respectful terminology. During meetings, the expert group hypothesised that inequalities in OAT access are likely to be linked to underlying rationales which in theory are contradictory, but in practice co-exist within the different political frameworks. The present article considers the perceived influence upon different regulatory frameworks. Discussion is centred around the potential impact of underlying rationales upon the effective implementation of a modernised framework.

Identifiants

pubmed: 34639456
pii: ijerph181910155
doi: 10.3390/ijerph181910155
pmc: PMC8508445
pii:
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Public Health. 2017 Dec;153:147-153
pubmed: 29055811
JAMA. 1965 Aug 23;193:646-50
pubmed: 14321530
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
N Y State J Med. 1966 Aug 1;66(15):2011-7
pubmed: 5220498
BMC Int Health Hum Rights. 2018 Nov 16;18(1):41
pubmed: 30445949
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732

Auteurs

Cheryl Dickson (C)

Addiction Medicine, Lausanne University Hospital (CHUV), 1004 Lausanne, Switzerland.

Valérie Junod (V)

Faculty of Law, University of Geneva, 1211 Genève, Switzerland.
Faculty of Business and Economics, University of Lausanne, 1011 Lausanne, Switzerland.

René Stamm (R)

Independant Counsultant, 3012 Bern, Switzerland.

Emilien Jeannot (E)

Addiction Medicine, Lausanne University Hospital (CHUV), 1004 Lausanne, Switzerland.
Faculty of Medicine, Institute of Global Health, Chemin de Mines 9, 1202 Geneva, Switzerland.

Robert Hämmig (R)

Dr. Robert Ltd. on behalf of the Swiss Society of Addiction Medicine, 3000 Bern, Switzerland.

Willem Scholten (W)

Willem Scholten Consultancy, NL-3411 AD Lopik, The Netherlands.

Olivier Simon (O)

Addiction Medicine, Lausanne University Hospital (CHUV), 1004 Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH